Liquid Biopsy and MRD Monitoring — Tumour DNA in blood is now a routine clinical measurement. Oncologists use it to choose therapy, track response and catch relapse months before imaging, and digital PCR's absolute counts at very low allele fractions make it the natural tool for known mutations. Oncology testing is already the largest application, at USD 626.8 Mn or 34.0% of 2025 revenue. Biodesix agreed in October 2025 to validate Bio-Rad's ddPLEX ESR1 assay for HR+/HER2- breast cancer, where ESR1 mutations guide use of oral SERD therapies, and it plans to seek CMS reimbursement. SAGA Diagnostics' Pathlight test pairs whole-genome sequencing with multiplex dPCR to follow structural variants, and Roche agreed to buy SAGA for up to USD 595 Mn in April 2026. GLOBOCAN counts about 20 million new cancer cases a year, which sets the size of the monitoring pool. Expect MRD and therapy-selection tests to keep converting oncology from a research application into a recurring clinical one through 2035.
Digital PCR Market Report: Size, Share & Trends 2026-2035
Digital PCR Market by Product (Instruments, Reagents & Consumables, Software & Services), by Application (Oncology Testing, Infectious Disease Testing, Genetic Disease Testing, Prenatal & Reproductive Testing and Transplant Monitoring), by Technology (Droplet Digital PCR, Chip-Based Digital PCR, Nanoplate-based & microfluidic digital PCR and BEAMing), by End User (Diagnostic Laboratories, Academic & Research Institutes, Pharma & Biotech Companies) and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Digital PCR Industry Perspective
The Global Digital PCR market was valued at USD 1,843.6 Mn in 2025 and is projected to reach USD 5,206.5 Mn by 2035, growing at a CAGR of 10.94% during the forecast period 2026–2035, according to Vectomat Insights.
North America is the largest regional market at 41.0% of 2025 revenue, while software and services, the fastest-growing product line at a 16.84% CAGR, shows value shifting from the instrument toward the analysis and service contract around it.
Digital PCR Market: Overview
Digital PCR encompasses the instruments that partition and read samples, the reagents, assay kits and plates or droplet consumables used on every run, and the analysis software and service contracts that support them. Partitioning methods include water-in-oil droplets, microfabricated chips and nanoplates, and bead-based BEAMing, each trading off partition count, throughput and cost. The report scope covers research, biopharma and clinical use across oncology, infectious disease, genetic disease and prenatal and transplant monitoring.
The value chain runs across three tiers. Foundational providers build and sell the platforms and the automation around them: Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific, Roche and Hamilton Company. Specialist developers bring new partitioning chemistry and hardware, including Stilla Technologies (now part of Bio-Rad), Countable Labs, BioTNS and Revosketch. Application-layer specialists turn those platforms into clinical tests and services, as Biodesix, SAGA Diagnostics and GENCURIX do in oncology.
For procurement and investment teams, the shift to watch is from capital to recurring revenue: consumables, assay menus and software now drive most of the forecast growth, while instrument placements slow. This report tracks that shift across 4 segmentation dimensions and 35+ countries, so buyers can see which sub-segments and geographies take the largest share of the USD 3,362.9 Mn of new annual revenue the market adds by 2035.
According to International Agency for Research on Cancer (IARC), GLOBOCAN 2022, February 2024, An estimated 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide in 2022, setting the size of the patient pool for dPCR-based tumour DNA monitoring.

Key Insights
- The Global Digital PCR market rises from USD 1,843.6 Mn in 2025 to USD 5,206.5 Mn by 2035, a 10.94% CAGR over 2026–2035, roughly 2.8 times its base-year size.
- Instruments are the largest product line at 44.0% of 2025 revenue (USD 811.2 Mn), but they compound at only 7.0% a year; reagents and consumables (USD 774.3 Mn) grow at 11.92% and become the biggest line, at USD 2,387.4 Mn, by 2035.
- Software & Services is the fastest-growing product category at a 16.84% CAGR, climbing from USD 258.1 Mn to USD 1,224.0 Mn as labs buy analysis software and service contracts alongside the box.
- Droplet digital PCR dominates the technology mix with 61.6% of 2025 revenue (USD 1,136.2 Mn); nanoplate-based, microfluidic and BEAMing formats are the fastest-growing at a 16.62% CAGR.
- Oncology testing is the largest application at 34.0% (USD 626.8 Mn), while infectious disease testing grows fastest at 14.58% a year and becomes the largest application, at USD 2,156.3 Mn, by 2035.
- Diagnostic laboratories hold 42.5% of 2025 revenue; pharma and biotech companies are the fastest-growing end user at a 15.59% CAGR on cell and gene therapy quality-control demand.
- North America leads with 41.0% of 2025 revenue (USD 755.9 Mn), and the United States alone accounts for USD 619.8 Mn; Asia Pacific is the fastest-growing region, with South Korea compounding at 13.1% a year.
- Consolidation is redrawing the vendor map: Bio-Rad bought Stilla Technologies for about USD 225 Mn in June 2025, Roche agreed to buy SAGA Diagnostics for up to USD 595 Mn in April 2026, and EQT agreed a EUR 10.8 Bn take-private of QIAGEN in October 2026.
- QIAGEN reported more than 3,200 cumulative QIAcuity placements in June 2026, with over 400 customers running multiple instruments.

Digital PCR Market: Report Scope
| Report Name | Digital PCR Market by Product (Instruments, Reagents & Consumables, Software & Services), by Application (Oncology Testing, Infectious Disease Testing, Genetic Disease Testing, Prenatal & Reproductive Testing and Transplant Monitoring), by Technology (Droplet Digital PCR, Chip-Based Digital PCR, Nanoplate-based & microfluidic digital PCR and BEAMing), by End User (Diagnostic Laboratories, Academic & Research Institutes, Pharma & Biotech Companies) and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 1,843.6 Mn (2025) |
| Market Forecast in 2035 | USD 5,206.5 Mn (2035) |
| Growth Rate (CAGR) | 10.94% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 98 tables & 72 figures |
| Report Code | VMI-1-3-97529 |
| Report Format | |
| Delivery Format | PDF via email delivery and online download portal |
| Published Date | 15 Nov 2026 |
| Research Methodology | Primary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation) |
| Key Companies Covered | Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific, Roche, Stilla Technologies, Countable Labs, Biodesix, SAGA Diagnostics, GENCURIX, BioTNS, Revosketch, Hamilton Company |
| Segments Covered | Product, Application, Technology, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Up to 10% free customization: additional country splits, extra company profiles or a custom segment cut |
Why This Digital PCR Market Report Matters
Decision-makers comparing market intelligence reports on Digital PCR will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 4 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 12 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
Why Is the Digital PCR Market Growing?
Wastewater and Outbreak Surveillance — Sewage became a public health dataset during COVID-19, and the programmes stayed. CDC's National Wastewater Surveillance System receives data from about 1,500 sampling sites in all 50 states, and CDC notes that most labs quantify viral material with RT-dPCR or RT-ddPCR, because partitioning tolerates the inhibitors common in wastewater. Commercial testers such as Verily run multiplexed dPCR for up to 400 facilities. New targets keep arriving: QIAGEN released two custom QIAcuity assays for Bundibugyo ebolavirus research and wastewater surveillance in May 2026, built from published outbreak sequences. Outside the U.S., South Africa's NICD runs dPCR on samples from 48 sites in 9 provinces. Infectious disease testing grows at 14.58% a year, the fastest of any application, and reaches USD 2,156.3 Mn by 2035.
Cell and Gene Therapy Quality Control — Release testing for viral vectors has no room for standard-curve drift. Cell and gene therapy manufacturers must report vector genome titre, residual host-cell DNA and replication-competent virus with tight precision, and digital PCR gives an absolute count without a reference curve. Pharma and biotech companies are the fastest-growing end user at a 15.59% CAGR, rising from USD 479.3 Mn in 2025 to USD 2,041.2 Mn by 2035. Vendors are packaging the workflow: Bio-Rad has added Vericheck ddPCR assays for cell and gene therapy, and QIAGEN has launched a HEK293 residual DNA sizing kit, with lentivirus detection kits planned for 2026. Automation matters in GMP settings, where QIAGEN's collaboration with Hamilton automates QIAcuity plate loading. QIAGEN's HEK293 resDNA Sizing Kit, which measures both host-cell DNA concentration and fragment size, is a working example of the category.
Platform Consolidation and Multiplex Launches — The leaders are buying breadth rather than building it. Bio-Rad closed its roughly USD 225 Mn purchase of Stilla Technologies on 30 June 2025 and, a week later, launched the QX Continuum alongside the QX700 series, which offers seven-colour multiplexing and capacity for more than 700 samples a day. QIAGEN answered in June 2026 with a 12-target RNA multiplex kit, thousands of planned gene expression assays and Software 3.5 for automated reporting. Higher plex counts cut cost per target, and higher throughput lets dPCR compete for work that used to default to qPCR. Bio-Rad's own framing is telling: it aims to expand the dPCR user base rather than replace the installed one. Structurally, this turns digital PCR from a specialist instrument into a platform category with entry, mid-range and high-throughput tiers.
Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.
With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad's presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions.
What's Limiting the Digital PCR Market?
Academic Funding and Capex Pressure — Research budgets, not interest, are holding back placements. Bio-Rad told investors in May 2025 that its Life Science business faced academic and biopharma funding headwinds, particularly in the U.S., and by July it described ddPCR instruments as relatively weak year over year even as ddPCR consumables grew at a high single-digit rate. That split shows up in the forecast: instruments grow at only 7.0% a year, while academic and research institutes grow at 5.92%, the slowest end-user rate. Long grant cycles stretch sales cycles for capital equipment. QIAGEN's CEO said in January 2026 that he expects lab capital spending to recover in the second half of 2026. If it doesn't, vendors will lean even harder on consumable pull-through from the existing base.
High Cost Per Sample Versus qPCR — For many routine tests, qPCR is good enough and cheaper. Digital PCR instruments carry five-figure price tags even on promotion, Bio-Rad advertised its QX200 at USD 39,000, and every run consumes proprietary plates, cartridges or droplet oil. When China's NMPA approved the country's first dPCR testing kit, its own notice listed expensive instruments and reagents, a more complex workflow and longer time to result as the technology's drawbacks. Labs therefore keep dPCR for low-abundance targets and send bulk work to qPCR. That keeps academic and research institutes, at 31.5% of 2025 revenue, growing at just 5.92% a year.
Tariffs and Supply Chain Exposure — Proprietary consumables make dPCR vendors sensitive to trade policy. Bio-Rad first estimated a tariff headwind of up to 130 basis points on its 2025 operating margin, then cut that to about 30-40 basis points by July through surcharges, pre-positioned stock and regional sourcing from Europe and Singapore. Customers with fixed budgets resist surcharges, and Bio-Rad noted that budgets limit how much it can pass through. China adds a second layer, with reimbursement cuts in diagnostics and local dPCR makers competing on price. Bio-Rad's mitigation, shifting product into China from non-U.S. plants, is now the template other vendors follow.
We faced a challenging macroenvironment, with academic market headwinds due to government funding and global trade disruptions from tariffs.
Emerging Opportunities in the Digital PCR Market
qPCR-to-dPCR Conversion in Gene Expression — The next big pool of demand is work that qPCR already does. QIAGEN said in January 2026 that it would launch thousands of new gene expression assays for QIAcuity during the year, and in June it added a kit that reads up to 12 RNA targets in one reaction. Its CEO has also disclosed investment in a second-generation system aimed partly at converting qPCR gene expression testing. Bio-Rad's QX Continuum, with a qPCR-like workflow and up to eight thermal profiles per plate, targets the same entry-level buyers. Structurally, every converted assay moves a lab from a reagent-only qPCR workflow to a platform with proprietary consumables.
Clinical IVD Menus and Reimbursement — Clinical menus are where dPCR revenue becomes sticky. Bio-Rad's QXDx BCR-ABL %IS kit was the first FDA-cleared dPCR test, in 2019, and it gained IVDR certification in November 2024. QIAGEN launched its QIAcuityDx Partnering Program in June 2025 with GENCURIX developing oncology assays, and Biodesix will seek CMS coverage for the ESR1 assay it validates on Bio-Rad's QX600. Diagnostic laboratories already account for USD 783.8 Mn, or 42.5% of 2025 revenue. As more kits clear the FDA, IVDR and NMPA, clinical laboratories should become the largest source of new consumable demand through the early 2030s.
Asia Pacific Platform Localisation — Asia Pacific governments want domestic dPCR supply, not just imported systems. South Korea selected BioTNS in June 2026 to lead a KRW 30 Bn programme on ultra-precision dPCR standards, GENCURIX joined a separate KRW 29.4 Bn early-cancer-detection project running to 2032, and Revosketch localised its MicroWell disc with the National NanoFab Center in December 2025. China already has NMPA Class III dPCR kits from domestic makers. Local platforms lower entry prices and pull hospital labs into the market. South Korea's dPCR market grows from USD 92.9 Mn in 2025 to about USD 318.2 Mn by 2035, a 13.1% CAGR.
What's Holding Back the Digital PCR Market?
Single-Molecule and NGS Competition — Digital PCR's sensitivity edge is being challenged from two sides. Countable Labs splits samples into about 30 million compartments, against roughly 20,000 for typical dPCR, won a CE mark in March 2026 and raised USD 26 Mn in May 2026 to push into MRD and gene therapy QC. Sequencing-based MRD tests from Natera and others compete for the same oncology monitoring budgets. Countable Labs now offers its platform through a certified service-provider programme launched in July 2026.
Assay Standardisation Across Laboratories — Absolute quantification doesn't guarantee comparable results between labs. In a 2024 proficiency-testing programme for CDC's wastewater network, replicate respiratory virus results from 38 laboratories spanned roughly two orders of magnitude, and NWSS prescribes no single workflow. Clinical labs face the same issue when laboratory-developed dPCR tests move to IVD kits. Standardisation is therefore a shared reference-material and proficiency-testing problem, not a single vendor's fix.
I like the simplicity of direct target counting, rather than relying on Poisson-based inference.

Where AI Fits Into the Digital PCR Market
AI is entering digital PCR at both ends of the workflow. At the bench, researchers have shown deep-learning models that segment and classify droplets in high-throughput ddPCR images, which speeds analysis and flags artefacts that threshold-based calls miss. At the front end, QIAGEN launched QIA Agent, an AI assistant that helps researchers plan experiments and pick assays, and its 2026 priorities include new AI tools for pharma R&D and clinical reporting.
For buyers, the near-term value is less in the instrument than in the software layer: automated calls, templates and audit-ready reports that cut hands-on analysis time and reduce inter-operator variation. That matters most in GMP release testing and multi-site clinical networks. It also helps explain why Software & Services is the fastest-growing product line in this market, at a 16.84% CAGR to USD 1,224.0 Mn by 2035.
Digital PCR Market: Segmentation
The Global Digital PCR market is segmented by Product, Application, Technology, End User.
By Product
The money in digital PCR is moving from the box to what runs through it. Instruments are still the largest product line at 44.0% of 2025 revenue (USD 811.2 Mn), because every new lab starts with a reader and partitioning hardware, but they compound at only 7.0% a year. Reagents and consumables, at 42.0% (USD 774.3 Mn), grow at 11.92% and overtake instruments well before 2035, reaching USD 2,387.4 Mn. Software & Services is the fastest-growing line at a 16.84% CAGR, rising from USD 258.1 Mn to USD 1,224.0 Mn as labs pay for analysis templates, automated reporting and service cover. QIAGEN's QIAcuity Software 3.5, released in June 2026 with pre-defined analysis templates and automated reports, is the kind of product driving that line.
Year-on-Year Digital PCR Market Revenue By Product (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Instruments | 638.5 | 687.2 | 811.2 |
| Reagents & Consumables | 659.1 | 751.8 | 774.3 |
| Software & Services | 238.4 | 239.4 | 258.1 |
By Application
Clinical demand is spreading beyond the oncology lab. Oncology testing is the largest application at 34.0% of 2025 revenue (USD 626.8 Mn), since rare-mutation detection in circulating tumour DNA plays to digital PCR's strength at low allele fractions. Infectious disease testing, at 30.0% (USD 553.1 Mn), is the fastest-growing application at a 14.58% CAGR and becomes the largest by 2035, at USD 2,156.3 Mn, as wastewater and outbreak programmes standardise on RT-dPCR. Genetic disease testing holds 20.0% and prenatal, reproductive and transplant monitoring 16.0%; the latter jumped 35.8% in 2025 alone but settles to an 8.01% CAGR. Biodesix's October 2025 deal to validate Bio-Rad's ddPLEX ESR1 assay for breast cancer shows how oncology menus are getting built.
Year-on-Year Digital PCR Market Revenue By Application (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Oncology Testing | 615.9 | 662.7 | 626.8 |
| Infectious Disease Testing | 443.7 | 487.3 | 553.1 |
| Genetic Disease Testing | 297.2 | 311.1 | 368.7 |
| Prenatal & Reproductive Testing and Transplant Monitoring | 179.2 | 217.3 | 295.0 |

By Technology
Partitioning method decides throughput, multiplexing and cost per sample, and buyers now weigh all three. Droplet digital PCR dominates with 61.6% of 2025 revenue (USD 1,136.2 Mn), backed by the largest installed base and assay catalogue, and still grows at 11.76% a year. Chip-based digital PCR takes 30.4% (USD 559.9 Mn) but grows more slowly, at 6.64%. Nanoplate-based, microfluidic and BEAMing formats are the fastest-growing at a 16.62% CAGR, rising from USD 147.5 Mn to USD 686.3 Mn by 2035, helped by qPCR-like plate workflows that suit high-volume labs. Bio-Rad's July 2025 QX700 series, with seven-colour multiplexing and capacity for over 700 samples a day, shows the droplet leader answering that throughput challenge.
Year-on-Year Digital PCR Market Revenue By Technology (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Droplet Digital PCR | 964.0 | 1,024.1 | 1,136.2 |
| Chip-Based Digital PCR | 477.1 | 533.8 | 559.9 |
| Nanoplate-based & microfluidic digital PCR and BEAMing | 94.9 | 120.5 | 147.5 |

By End User
Clinical validation, not research curiosity, now sets the pace of purchasing. Diagnostic laboratories are the largest end user at 42.5% of 2025 revenue (USD 783.8 Mn), because validated oncology and transplant assays run at volume and pull consumables every day. Academic and research institutes hold 31.5% (USD 580.5 Mn) but grow slowest, at 5.92% a year, as grant budgets tighten. Pharma and biotech companies are the fastest-growing end user at a 15.59% CAGR, climbing from USD 479.3 Mn to USD 2,041.2 Mn by 2035 on cell and gene therapy release testing. QIAGEN's HEK293 resDNA Sizing Kit, launched for host-cell DNA measurement in biopharma manufacturing, is a typical purchase in this group.
Year-on-Year Digital PCR Market Revenue By End User (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Diagnostic Laboratories | 630.0 | 713.1 | 783.8 |
| Academic & Research Institutes | 476.6 | 518.0 | 580.5 |
| Pharma & Biotech Companies | 429.4 | 447.3 | 479.3 |

Digital PCR Market: Production & Volume Analysis, 2025
This section counts systems installed: digital PCR instruments in active use at the end of 2025. Vectomat Insights estimates the global installed base at about 21,400 systems, which implies roughly USD 86,150 of annual market revenue per installed system across instruments, consumables and service. Droplet systems lead on both counts: 52.0% of units, 61.6% of revenue. Nanoplate, microfluidic and BEAMing systems hold 15.0% of units but only 8.0% of revenue, a volume-value split typical of newer placements still ramping consumable use; QIAGEN alone reported more than 3,200 cumulative QIAcuity placements by June 2026. Chip-based platforms make up the other 33.0%.
| Metric | 2025 Volume (systems installed) | Share of Units |
|---|---|---|
| Total systems installed (2025) | 21,400 | 100.0% |
| Droplet Digital PCR | 11,128 | 52.0% |
| Chip-Based Digital PCR | 7,062 | 33.0% |
| Nanoplate-based & microfluidic digital PCR and BEAMing | 3,210 | 15.0% |
Reference point: QIAGEN — Reported more than 3,200 cumulative QIAcuity digital PCR placements worldwide since launch, with over 400 customers operating multiple instruments (June 2026). 3,200+ cumulative placements.
Digital PCR Market: Competitive Landscape
Ownership in digital PCR changed hands at a pace the market hasn't seen before. Bio-Rad remains the clear leader: its droplet installed base underpins the 61.6% revenue share held by droplet digital PCR, and buying Stilla added high-plex chip systems at the top of the range. QIAGEN is the strongest challenger, with more than 3,200 QIAcuity placements, and its pending sale to EQT may free it to invest in a second-generation system. Thermo Fisher competes on integrated, low-touch workflows. Roche is betting on decentralised MRD testing. Specialists in South Korea and new single-molecule counters such as Countable Labs push on price and sensitivity. Key players include Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific, Roche, Stilla Technologies, Countable Labs, Biodesix, SAGA Diagnostics, GENCURIX, BioTNS, Revosketch and Hamilton Company, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Bio-Rad Laboratories | United States | Droplet Digital PCR systems (QX200, QX600, QX Continuum, QX700 series), ddPCR reagents and FDA-cleared QXDx clinical kits | Full-range ddPCR portfolio plus clinical oncology assay partnerships | Launched four new ddPCR platforms, including the QX Continuum and the QX700 series, in July 2025 after closing the Stilla Technologies acquisition on 30 June 2025 |
| QIAGEN | Netherlands | QIAcuity nanoplate dPCR systems, QIAcuityDx clinical platform, GeneGlobe assays and CGT quality-control kits | Convert qPCR workflows to dPCR through gene expression assays and automation | Agreed in October 2026 to a EUR 10.8 Bn all-cash take-private by EQT, after reporting more than 3,200 cumulative QIAcuity placements in June 2026 |
| Thermo Fisher Scientific | United States | QuantStudio Absolute Q microfluidic-array dPCR system, Absolute Q AutoRun automation suite and TaqMan-based dPCR assays | Integrated, low hands-on-time dPCR tied to its TaqMan assay catalogue | Reported third-quarter 2026 Life Sciences Solutions revenue of USD 2.72 Bn, up 5.1%, in October 2026; the segment houses its Absolute Q dPCR line |
| Roche | Switzerland | Digital LightCycler dPCR system for oncology, transplant and infectious disease testing | Pair dPCR hardware with MRD testing through Foundation Medicine | Agreed in April 2026, through Foundation Medicine, to acquire SAGA Diagnostics for up to USD 595 Mn, with plans for a decentralised MRD solution on the Digital LightCycler |
| Stilla Technologies | France | Crystal digital PCR and the Nio family of high-multiplex, all-in-one systems, now sold as Bio-Rad's QX700 series | High-plex chip-based dPCR scaled through Bio-Rad's global channel | Acquired by Bio-Rad on 30 June 2025 for about USD 225 Mn in cash plus up to USD 50 Mn in milestones |
| Countable Labs | United States | Countable PCR, a single-molecule counting platform using about 30 million partitions in a gel matrix | Position single-molecule counting against dPCR and NGS in CGT and MRD | Won a CE mark in March 2026 and closed an oversubscribed USD 26 Mn financing round led by ARCH Venture Partners in May 2026 |
| Biodesix | United States | ddPCR-based lung and breast cancer tests and assay development services from its CLIA-CAP laboratory | Clinical validation and reimbursement for partner ddPCR assays | Expanded its Bio-Rad partnership in October 2025 to develop, validate and submit ddPCR IVD assays, starting with the ddPLEX ESR1 Mutation Detection Assay |
| SAGA Diagnostics | Sweden | Pathlight tumour-informed MRD test combining whole-genome sequencing with digital PCR, plus SAGAsafe dPCR assays | Structural-variant MRD tracking at ultra-low detection limits | Agreed in April 2026 to be acquired by Roche's Foundation Medicine for up to USD 595 Mn |
| GENCURIX | South Korea | Oncology and methylation-based dPCR liquid biopsy assays | Build IVD assay menus for third-party and domestic dPCR platforms | Joined QIAGEN's QIAcuityDx Partnering Program in June 2025 and became a joint R&D partner in a KRW 29.4 Bn government dPCR cancer-detection project in June 2026 |
| BioTNS | South Korea | LQ Suite microdroplet digital PCR platform and blood cancer liquid biopsy kits | Lead domestic standards and clinical validation for Korean dPCR | Selected in June 2026 to lead a KRW 30 Bn government programme for ultra-precision digital PCR technical standards |
| Revosketch | South Korea | digiQuark microwell-disc digital PCR for cancer mutation detection | Localised, semiconductor-made consumables to cut dPCR cost | Completed mass-production technology for its MicroWell disc with the National NanoFab Center in December 2025, localising a core component of its digiQuark dPCR device |
| Hamilton Company | United States | Liquid-handling automation that loads and processes QIAcuity dPCR plates | Automation partner for GMP and high-throughput dPCR workflows | Featured in QIAGEN's June 2026 QIAcuity portfolio update as the automation partner customers can use to automate QIAcuity workflows |
Strategic activity clusters around three themes. First, consolidation: Bio-Rad bought Stilla in June 2025, Roche agreed to buy SAGA Diagnostics in April 2026 and EQT agreed to take QIAGEN private in October 2026. Second, clinical menus, with QIAGEN's QIAcuityDx Partnering Program and Biodesix's ESR1 work turning research platforms into IVD franchises. Third, automation and multiplexing, from Bio-Rad's seven-colour QX700 to QIAGEN's 12-target RNA kit and Hamilton loading. Expect pricing to tighten as Korean platforms scale.

Digital PCR Market: From Raw Material to Delivery
Partitioning Hardware and Consumables Manufacturing — Platform makers design the droplet generators, microfluidic chips, nanoplates and optical readers, and they manufacture the plates, cartridges, oils and master mixes used on every run. Consumables are proprietary to each platform, which is what gives vendors recurring revenue. Component localisation is now a policy goal, as Revosketch's MicroWell disc, made with Korea's National NanoFab Center, shows. Key Players: Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific, Roche, Stilla Technologies, Revosketch.
Assay Development, Automation and Distribution — Assay developers design and validate primer-probe sets for mutations, pathogens, vector titres and copy-number targets, while automation suppliers integrate plate loading and analysis so a platform can run unattended. Catalogue depth matters: Bio-Rad cites more than 400,000 ddPCR assays and QIAGEN's GeneGlobe links to over 10 million predesigned designs. Distributors and service providers extend reach into smaller markets. Key Players: QIAGEN, Bio-Rad Laboratories, Hamilton Company, GENCURIX, BioTNS.
Clinical, Biopharma and Public Health Use — End users turn partitions into decisions: oncology labs monitor tumour DNA, transplant and haematology services track residual disease, biopharma QC teams release vector batches, and public health labs report wastewater trends. Clinical value depends on validation and reimbursement, which is why labs such as Biodesix seek CMS coverage for each assay. New counting methods are entering at this stage. Key Players: Biodesix, SAGA Diagnostics, Roche, Countable Labs.
Digital PCR Market: Regional Analysis
North America leads the Global Digital PCR market with 41.0% of 2025 revenue, built on CDC-funded wastewater testing, early FDA-cleared ddPCR assays and the largest oncology reference-lab networks. Asia Pacific is the fastest-growing region, as South Korea funds domestic dPCR platforms and Japan reimburses digital PCR liquid biopsy.
North America Digital PCR Market
Public health and oncology both fund digital PCR in North America, which is why the region holds 41.0% of the 2025 market (USD 755.9 Mn). The United States contributes USD 619.8 Mn and is forecast to grow at a 9.7% CAGR to about USD 1,564.3 Mn by 2035. CDC's wastewater network now receives data from roughly 1,500 sampling sites in all 50 states, and most of those labs quantify with RT-dPCR or RT-ddPCR. Clinical menus are widening too, with Biodesix validating Bio-Rad's ddPLEX ESR1 assay in its CLIA-CAP lab. The brake is academic spending: Bio-Rad reported weak U.S. research demand through 2025. Growth will lean on clinical and public health volume, not new university placements, through the forecast horizon.
United States Digital PCR Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 619.8 Mn |
| Forecast Value (2035) | USD 1,564.3 Mn |
| CAGR (2026–2035) | 9.7% |

Europe Digital PCR Market
Europe is home to two of the market's defining technology stories: QIAGEN's QIAcuity, run from Hilden in Germany, and Stilla Technologies, the French developer Bio-Rad bought in June 2025. The region takes 24.74% of 2025 revenue (USD 456.17 Mn). Germany is the largest country market at USD 119.5 Mn, growing at a 9.3% CAGR to about USD 290.8 Mn by 2035, supported by a dense network of university hospitals and molecular reference labs. Regulation cuts both ways: IVDR certification opens all member states to a cleared kit, but the transition, now running to 2029, raises the cost of every clinical submission. Countable Labs' CE mark in March 2026 adds a new competitor. Germany alone adds about USD 171.3 Mn of annual revenue by 2035.
Germany Digital PCR Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 119.5 Mn |
| Forecast Value (2035) | USD 290.8 Mn |
| CAGR (2026–2035) | 9.3% |

Asia Pacific Digital PCR Market
Industrial policy is shaping digital PCR in Asia Pacific more than anywhere else. The region holds 23.81% of 2025 revenue (USD 439.02 Mn) and is the fastest-growing region in the forecast. South Korea is the standout: a USD 92.9 Mn market in 2025 compounding at 13.1% to about USD 318.2 Mn by 2035. Japan, larger at USD 128.3 Mn, has reimbursed Sysmex's OncoBEAM RAS CRC digital PCR liquid biopsy since August 2020, while China's TargetingOne won the country's first Class III approval for a dPCR kit. Price pressure from local platforms is the main headwind. In June 2026 BioTNS was chosen to lead a KRW 30 Bn government programme to set technical standards for ultra-precision dPCR, with seven university hospitals in its consortium.
South Korea Digital PCR Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 92.9 Mn |
| Forecast Value (2035) | USD 318.2 Mn |
| CAGR (2026–2035) | 13.1% |

Latin America Digital PCR Market
Most digital PCR demand in Latin America comes through private laboratories rather than public tenders. The region accounts for 5.0% of 2025 revenue (USD 92.2 Mn), and Brazil is the largest market, where private reference labs and cancer centres use dPCR for liquid biopsy, BCR-ABL monitoring and transplant work. Argentina, Colombia and Chile follow at smaller scale. Imported instruments and reagents carry duties and currency risk, so labs tend to buy one platform and run it hard. In structural terms the region is a consumables market riding on a thin installed base, where each new clinical assay adds more revenue than each new box.
The Middle East Digital PCR Market
Gulf health authorities are formally assessing digital PCR for hospital use. The Middle East holds 3.07% of 2025 revenue (USD 56.6 Mn), led by the GCC, where Abu Dhabi's Department of Health has published a technology-status review of Bio-Rad's QXDx AutoDG ddPCR system. Israel adds research and biotech demand, and Turkey's university hospitals form a third cluster. Demand is concentrated in a handful of tertiary centres, so test volumes outside them remain low. As national genomics and cancer programmes in Saudi Arabia and the UAE scale up, the region should keep adding clinical placements through the forecast period.
Africa Digital PCR Market
Public health surveillance, not hospital diagnostics, is the entry point for digital PCR in Africa. The region takes 2.38% of 2025 revenue (USD 43.81 Mn), with South Africa and Egypt the largest markets. South Africa's National Institute for Communicable Diseases built a grant-funded wastewater network of 48 treatment-plant and district sites across 9 provinces and tests the samples with dPCR for SARS-CoV-2, measles, rubella and hepatitis. Funding depends heavily on grants, and the NICD has reported delays in shipping PCR reagents. With 48 sites across 9 provinces, South Africa's network is the largest dPCR deployment on the continent.


Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
How Governments Are Supporting the Digital PCR Market
National wastewater surveillance — CDC set up the National Wastewater Surveillance System in 2020 and now receives data from about 1,500 sampling sites in all 50 states; most participating labs quantify pathogens with RT-dPCR or RT-ddPCR, and more than 456,500 samples from 139 labs were submitted in 2020–2024. (CDC National Wastewater Surveillance System (NWSS))
Domestic dPCR platform development — In June 2026 South Korea selected BioTNS to lead a KRW 30 Bn (about USD 19.5 Mn) multi-ministerial programme to set technical standards for ultra-precision digital PCR, backed by the National NanoFab Center, the Korea Research Institute of Bioscience and Biotechnology and seven university hospitals. (Pan-Ministerial Advanced Medical Device R&D Programme (ultra-precision digital PCR))
Harmonised diagnostic regulation — Regulation (EU) 2024/1860 extended the IVDR transition so that legacy diagnostic kits can stay on the market while manufacturers certify them, giving dPCR kit makers until the end of the decade to move clinical assays onto CE-IVD labels. (EU In Vitro Diagnostic Regulation (Regulation (EU) 2017/746, amended by 2024/1860))
Public health capacity in emerging markets — South Africa's National Institute for Communicable Diseases built a grant-funded network of 48 wastewater sampling sites across 9 provinces and uses dPCR assays to track SARS-CoV-2, measles, rubella and hepatitis A and E. (NICD national wastewater-based surveillance network)
What's New in the Digital PCR Market?
Recent activity is dominated by ownership changes and portfolio expansion: three acquisitions or take-private deals in 16 months, alongside new platforms, clinical assay partnerships and outbreak-response assays.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Jul 2025 | Bio-Rad Laboratories | Product Launch | Launched four new Droplet Digital PCR platforms, the QX Continuum system and the QX700 series acquired with Stilla Technologies, a week after closing the Stilla deal. [source] | Gives the droplet leader entry-level, translational and high-throughput tiers, including seven-colour multiplexing and 700+ samples a day. |
| Oct 2025 | Biodesix | Partnership | Expanded its partnership with Bio-Rad to develop, clinically validate and submit ddPCR IVD assays on the QX600, starting with the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer. [source] | Moves a multiplex ddPCR oncology assay toward IVD status and CMS reimbursement in a CLIA-CAP lab. |
| Apr 2026 | Roche (Foundation Medicine) | M&A | Agreed to acquire SAGA Diagnostics, whose Pathlight MRD test combines whole-genome sequencing with digital PCR, for up to USD 595 Mn. [source] | Brings a dPCR-based MRD test into Roche, which plans a decentralised MRD solution on its Digital LightCycler platform. |
| May 2026 | Countable Labs | Investment | Closed an oversubscribed USD 26 Mn financing round led by ARCH Venture Partners to fund clinical product development and global sales of Countable PCR. [source] | Funds a single-molecule challenger aimed at dPCR's MRD and cell and gene therapy applications. |
| May 2026 | QIAGEN | Other | Made two custom QIAcuity digital PCR assays targeting the NP and VP35 regions of Bundibugyo ebolavirus available for research and wastewater surveillance. [source] | Shows how quickly dPCR assays can be deployed from published outbreak sequences, without standard curves. |
| Oct 2026 | QIAGEN | M&A | Agreed to an all-cash public takeover offer from EQT at EUR 46.50 per share, valuing the company at about EUR 10.8 Bn, with closing targeted for mid-2027. [source] | Puts the second-largest dPCR platform vendor into private ownership, with more room for long-term R&D spending. |
Research Methodology
Overall approach
VMI sized the Digital PCR market bottom-up and top-down. The bottom-up model starts from the installed base of dPCR systems by technology and end user, then applies annual consumable pull-through, assay menu use and service revenue per system. The top-down model reconciles that result with reported revenue from the leading vendors' life science and digital PCR franchises, adjusted for non-dPCR content.
Primary research
Primary inputs came from interviews with clinical and reference laboratory directors, cell and gene therapy quality-control managers, public health and wastewater laboratory leads, academic core facility managers and product and distribution staff at instrument vendors. Interviews tested instrument utilisation, plates or cartridges consumed per week, assay mix by application and expected replacement cycles.
Secondary research
Secondary research drew on company annual reports, SEC 10-K and 10-Q filings, earnings-call transcripts and investor presentations, FDA 510(k) and IVDR certification records, NMPA registrations, CDC National Wastewater Surveillance System publications, peer-reviewed dPCR literature and GLOBOCAN cancer-incidence data.
Data validation
Segment, regional and country values were reconciled to the 2025 base-year total of USD 1,843.6 Mn, so every dimension sums to the market size. Country values for the United States, Germany and South Korea were checked against their regional totals, and growth rates were cross-checked against reported vendor revenue trends and disclosed installed-base figures such as QIAGEN's QIAcuity placements.
Market Coverage Definitions
How this report defines the scope of the Digital PCR Market: what each segment and sub-segment includes.
| Segment | Market Coverage Definition |
|---|---|
| By Product | Segments the market by what is purchased, covering instruments, reagents and consumables, and software and services. |
| By Application | Segments the market by the testing purpose, covering oncology testing, infectious disease testing, genetic disease testing, and other applications. |
| By Technology | Segments the market by the partitioning method used, covering droplet digital PCR, chip-based digital PCR, and other technologies. |
| By End User | Segments the market by the type of organization running digital PCR tests, covering diagnostic laboratories, academic and research institutes, and pharma and biotech companies. |
By Product
| Sub-Segment | Market Coverage Definition |
|---|---|
| Instruments | Benchtop digital PCR systems that partition a sample and read partitions for target presence or absence, the largest product category given the capital cost of the instrument itself relative to per-run consumables. |
| Reagents & Consumables | Assay kits, partitioning plates or droplet generation supplies, and other per-run consumables required to run a digital PCR test, representing a recurring revenue stream tied to the installed instrument base. |
| Software & Services | Data analysis software, instrument service contracts, and application support services associated with digital PCR instruments. |
By Application
| Sub-Segment | Market Coverage Definition |
|---|---|
| Oncology Testing | Digital PCR testing for cancer applications, including minimal residual disease monitoring and treatment response tracking, the largest application given the technology's precision in detecting rare mutant sequences against a high background of normal DNA. |
| Infectious Disease Testing | Digital PCR testing for pathogen detection and quantification, including viral load monitoring and outbreak surveillance applications where absolute quantification without a standard curve is valuable. |
| Genetic Disease Testing | Digital PCR testing for inherited genetic conditions, including copy number variation analysis and rare variant detection. |
| Others | Additional applications, including cell and gene therapy quality control, environmental and food testing, and gene expression research. |
By Technology
| Sub-Segment | Market Coverage Definition |
|---|---|
| Droplet Digital PCR | Digital PCR that partitions a sample into thousands of individual water-in-oil droplets, the largest technology category and the most widely adopted digital PCR format across research and clinical applications. |
| Chip-Based Digital PCR | Digital PCR that partitions a sample across thousands of microfabricated wells or chambers on a chip or plate rather than into droplets, offering an alternative partitioning approach with its own throughput and automation characteristics. |
| Others | Additional digital PCR partitioning technologies and emerging single-molecule quantification approaches positioned as alternatives to conventional digital PCR. |
By End User
| Sub-Segment | Market Coverage Definition |
|---|---|
| Diagnostic Laboratories | Clinical and reference laboratories running digital PCR tests for patient diagnosis and monitoring, the largest end-user group given the growing clinical adoption of digital PCR for oncology and infectious disease testing. |
| Academic & Research Institutes | Universities and research institutions using digital PCR for basic research applications, including gene expression analysis and genetic variant detection. |
| Pharma & Biotech Companies | Pharmaceutical and biotechnology companies using digital PCR for drug development support, including cell and gene therapy quality control and clinical trial biomarker testing. |
Market Assessment Framework
The four-step framework used to size and validate the Digital PCR market.
- 1
Bottom-Up Approach
Market value is built up from individually identified digital PCR instruments, reagents and consumables, and software and services, starting with installed instrument base and per-run consumable consumption by technology type. Revenue for each category is aggregated upward to the product, application, and total market level.
- 2
Volume-Based Assessment
Instrument placement and test run volume are estimated separately for diagnostic laboratories, academic and research institutes, and pharma and biotech companies, since these end users run different testing volumes and consumable replenishment rates. Run frequency is also modeled by application, since oncology testing, infectious disease testing, and genetic disease testing follow different testing cadences.
- 3
Price & Revenue Benchmarking
Instrument and per-run consumable pricing is benchmarked against publicly disclosed list prices and distributor data, adjusted for regional procurement differences. Benchmarking distinguishes between droplet-based and chip-based digital PCR systems, which carry different instrument price points and per-sample consumable costs.
- 4
Market Validation & Triangulation
Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported instrument placements and revenue, regulatory clearance decisions, and publicly announced acquisition, product launch, and funding activity affecting digital PCR instrument and consumable supply. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.
Specialized Analyst Insights
Bio-Rad's acquisition of Stilla Technologies and its subsequent launch of the QX Continuum and QX700 platforms show a consolidation strategy built on both organic development and acquisition rather than either alone. Rather than building a high-multiplex, high-throughput platform entirely in-house, Bio-Rad absorbed Stilla's existing technology and brought it to market within roughly five months of the acquisition announcement, a pace that suggests the acquired platform was close to commercial readiness and that speed to market mattered more than fully internal development.
QIAGEN's approach has leaned toward organic platform expansion, adding gene expression assays, automation integration, and expanded cell and gene therapy quality control applications to its existing QIAcuity system rather than acquiring additional technology. With more than 3,200 cumulative instrument placements and over 400 customers running multiple instruments, QIAGEN's strategy appears focused on deepening usage within its existing installed base rather than expanding that base through acquisition.
QIAGEN's rapid deployment of custom digital PCR assays for Bundibugyo ebolavirus surveillance, built from publicly released outbreak sequences, illustrates digital PCR's practical advantage in public health response: absolute quantification without a standard curve allows faster assay deployment against a novel or re-emerging pathogen than methods requiring extensive calibration. This kind of rapid-response capability is likely to remain a differentiator for digital PCR against newer quantification technologies still establishing a public health track record.
Countable Labs' $26 million funding round for a single-molecule quantification platform explicitly positioned as outperforming digital PCR is an early signal that digital PCR's core applications, including minimal residual disease testing and cell and gene therapy quality control, are attracting competitive technology approaches beyond digital PCR itself. Established digital PCR vendors should treat this as an early-stage but credible competitive signal rather than a validated market displacement, given the technology remains in early clinical development.
Regional Regulations
Regulatory authorities and requirements across 9 jurisdictions
| Region | Key Regulatory Authorities / Frameworks | Government Regulations and Regulatory Considerations |
|---|---|---|
| North AmericaU.S. | U.S. FDA | Digital PCR instruments and assays used for research purposes are exempt from FDA premarket review, while those marketed for clinical diagnostic use require 510(k) clearance or, for laboratory-developed tests, fall under CMS/CLIA oversight. The FDA has cleared digital PCR systems and companion tests for specific oncology monitoring applications. |
| Europe | European Commission, Notified Bodies | Digital PCR instruments and assays marketed for diagnostic use in Europe require IVDR certification, while research-use-only instruments and assays fall outside IVDR scope. Several digital PCR platforms have obtained IVDR certification for oncology and infectious disease applications. |
| Asia PacificJapan | MHLW, PMDA | Digital PCR systems marketed for clinical diagnostic use in Japan are regulated under the Pharmaceuticals and Medical Devices Act, with PMDA reviewing assay performance data as part of approval. |
| Asia PacificChina | NMPA | China's NMPA regulates digital PCR systems and companion diagnostic assays as medical devices when marketed for clinical use, with registration requirements that vary by risk classification and growing domestic manufacturing of digital PCR instruments. |
| Asia PacificIndia | CDSCO | Digital PCR systems marketed for diagnostic use in India fall under the Medical Device Rules administered by the CDSCO, while research-use-only instruments generally fall outside device registration requirements. |
| Asia PacificSouth Korea | MFDS | South Korea's Ministry of Food and Drug Safety regulates digital PCR systems as medical devices when marketed with a diagnostic claim, with growing clinical adoption supported by national molecular diagnostics reimbursement policy. |
| Latin AmericaBrazil | ANVISA | Digital PCR systems marketed for diagnostic use are regulated as medical devices by ANVISA, with research-use-only instruments generally outside medical device registration requirements. |
| Middle East | National health product regulatory authorities, GCC frameworks | Digital PCR regulation continues to develop across the region alongside growing investment in molecular diagnostics and public health surveillance infrastructure. |
| Global / International | ISO, CDC | ISO standards support quality management and performance validation for digital PCR instruments and assays, while public health bodies including the CDC have endorsed digital PCR technology for applications such as wastewater-based infectious disease surveillance. |
Strategic Activities
5 strategic developments shaping the Digital PCR Market
| Date | Company / Companies | Development Type | Development and Impact on Market |
|---|---|---|---|
| Feb 2025 | Bio-Rad Laboratories, Stilla Technologies | Acquisition | Bio-Rad Laboratories entered a binding offer to acquire all equity interests in Stilla Technologies, a French and U.S. digital PCR developer known for its Nio family of all-in-one digital PCR systems. Bio-Rad said the deal would support expansion into applied research and clinical diagnostics, where customers want more automation and throughput, complementing Bio-Rad's existing digital PCR portfolio. [source] |
| Jul 2025 | Bio-Rad Laboratories | Product Launch | Bio-Rad launched four new droplet digital PCR platforms, including the QX Continuum system aimed at translational research and the QX700 series targeting academic research and biopharma quality control with seven-color multiplexing and throughput of over 700 samples per day. The QX700 series incorporated technology gained through Bio-Rad's acquisition of Stilla Technologies. [source] |
| May 2026 | Countable Labs | Funding | Countable Labs, a precision genomics company developing a single-molecule quantification platform it positions as outperforming digital PCR in sensitivity and precision, raised an oversubscribed $26 million round led by ARCH Venture Partners with participation from F-Prime Capital and Primer Ventures. The company said the funding would speed clinical development and global commercialization targeting oncology, cell and gene therapy manufacturing, and minimal residual disease testing, applications that overlap directly with established digital PCR use cases. [source] |
| Jun 2026 | QIAGEN | Public Health Application | QIAGEN made available two custom-designed digital PCR assays, targeting the nucleoprotein and VP35 regions of Bundibugyo ebolavirus, for research use on its QIAcuity digital PCR system to support surveillance of an active outbreak. The assays were developed from publicly available outbreak genomic sequences and were intended for research, wastewater surveillance, and environmental monitoring rather than direct patient diagnosis. [source] |
| Jun 2026 | QIAGEN | Product Expansion | QIAGEN held a QIAcuity Deep Dive event for investors, announcing new gene expression assays, a high-multiplex RNA probe kit, expanded cell and gene therapy residual DNA testing, an updated software release, and a Hamilton automation integration for high-throughput labs. The company reported more than 3,200 cumulative QIAcuity placements worldwide and over 400 customers operating multiple instruments. [source] |
Related Analysis
Blog · Diagnostics & MonitoringBio-Rad Is Buying Its Way Into Digital PCR's Next Act. QIAGEN Is Building It In-House.
The two biggest names in digital PCR are taking opposite paths to the same goal, while a well-funded newcomer argues the whole category is about to be leapfrogged and a real-world Ebola outbreak quietly shows why the technology still matters.
Read the article →Table of Contents: Digital PCR Market Report
14 chapters · 98 tables & 72 figures. Expand a chapter to see its sub-sections.
Introduction
- Report Description and Scope
- Market Definition and Coverage
- Research Assumptions and Abbreviations
Research Methodology
- Primary Research
- Secondary Research
- Market Size Estimation and Triangulation
Executive Summary
- Market Snapshot 2025–2035
- Key Findings and Analyst View
Market Dynamics
- Growth Drivers
- Restraints
- Opportunities
- Challenges
- Role of AI in Digital PCR
- Porter's Five Forces Analysis
Digital PCR Market: Segmentation By Product
- Product Overview and Share Analysis, 2025
- Instruments
- Reagents & Consumables
- Software & Services
- Production & Volume Analysis, 2025 (systems installed)
Digital PCR Market: Segmentation By Application
- Application Overview and Share Analysis, 2025
- Oncology Testing
- Infectious Disease Testing
- Genetic Disease Testing
- Prenatal & Reproductive Testing and Transplant Monitoring
Digital PCR Market: Segmentation By Technology
- Technology Overview and Share Analysis, 2025
- Droplet Digital PCR
- Chip-Based Digital PCR
- Nanoplate-based & microfluidic digital PCR and BEAMing
Digital PCR Market: Segmentation By End User
- End User Overview and Share Analysis, 2025
- Diagnostic Laboratories
- Academic & Research Institutes
- Pharma & Biotech Companies
Digital PCR Market: Regional Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Digital PCR Market: Competitive Landscape
- Market Share Analysis of Key Players, 2025
- Competitive Positioning Matrix
- Strategic Developments: Acquisitions, Launches and Partnerships
Company Profiles
- Company Overview, Digital PCR Portfolio, Financials and Recent Developments
Value Chain and Supply Chain Analysis
- Components, Partitioning Hardware and Consumables Supply
- Assay Development and Distribution
- Clinical and Research End Use
Regulatory and Policy Environment
- FDA, IVDR and NMPA Pathways for Digital PCR Assays
- Public Health Surveillance Programs
Appendix
- Glossary of Terms
- About Vectomat Insights
List of Tables (selected)
- Digital PCR Market Size, 2023–2035 (USD Million)
- Year-on-Year Digital PCR Market Revenue By Product (2023–2025, USD Million)
- Year-on-Year Digital PCR Market Revenue By Application (2023–2025, USD Million)
- Year-on-Year Digital PCR Market Revenue By Technology (2023–2025, USD Million)
- Year-on-Year Digital PCR Market Revenue By End User (2023–2025, USD Million)
- Digital PCR Market Forecast By Product, 2026–2035 (USD Million)
- Digital PCR Market Forecast By Application, 2026–2035 (USD Million)
- Digital PCR Market Forecast By Technology, 2026–2035 (USD Million)
- Digital PCR Market Forecast By End User, 2026–2035 (USD Million)
- Digital PCR Market Production & Volume, By Product, 2025 (systems installed)
- Digital PCR Market Size By Region, 2023–2035 (USD Million)
- North America Digital PCR Market Size By Country, 2023–2035 (USD Million)
- Europe Digital PCR Market Size By Country, 2023–2035 (USD Million)
- Asia Pacific Digital PCR Market Size By Country, 2023–2035 (USD Million)
- Latin America Digital PCR Market Size By Country, 2023–2035 (USD Million)
- The Middle East Digital PCR Market Size By Country, 2023–2035 (USD Million)
- Africa Digital PCR Market Size By Country, 2023–2035 (USD Million)
- Key Companies in the Digital PCR Market: Focus, Strategy and Recent Actions
- Recent Developments in the Digital PCR Market, 2025–2026
List of Figures (selected)
- Digital PCR Market Size, 2025–2035 (USD Million)
- Digital PCR Market: Drivers, Restraints, Opportunities & Challenges
- Digital PCR Market Share by Region, 2025
- Digital PCR Market — Segmentation Overview
- Digital PCR Market Share, By Product, 2025 (%)
- Digital PCR Market Share, By Application, 2025 (%)
- Digital PCR Market — Product Mix by Region
- Digital PCR Market — Competitive Landscape
- Digital PCR Market — At a Glance
- United States Digital PCR Market Size, USD Million
- Germany Digital PCR Market Size, USD Million
- South Korea Digital PCR Market Size, USD Million
You May Also Be Interested In
Liquid Biopsy Market
Shares oncology laboratory buyers and tumour DNA monitoring demand
Molecular Diagnostics Market
Parent diagnostics category spanning qPCR, dPCR and sequencing
Next-Generation Sequencing Market
Competing and complementary technology for MRD and genetic testing
Cell and Gene Therapy Manufacturing Market
Key buyer of dPCR for vector titre and release testing
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
What does the VMI Digital PCR market report include?
The report includes market sizing for 2023–2025 and forecasts to 2035 across 4 segmentation dimensions: product, application, technology and end user. It covers 6 regions and 35+ countries, a production and volume analysis of systems installed, 12 company profiles, a full drivers-restraints-opportunities-challenges framework, recent developments and a detailed table of contents with 98 tables and 72 figures, according to Vectomat Insights.
How big is the digital PCR market by technology?
Droplet digital PCR generated USD 1,136.2 Mn in 2025, a 61.6% share, and grows at 11.76% a year. Chip-based digital PCR contributed USD 559.9 Mn, or 30.4%, growing at 6.64%. Nanoplate-based, microfluidic and BEAMing formats are the smallest group at USD 147.5 Mn but the fastest-growing at a 16.62% CAGR, reaching USD 686.3 Mn by 2035, according to Vectomat Insights.
Which product category grows fastest in digital PCR?
Software & Services is the fastest-growing product category at a 16.84% CAGR, rising from USD 258.1 Mn in 2025 to USD 1,224.0 Mn in 2035. Reagents and consumables, at 11.92% a year, overtake instruments as the largest line and reach USD 2,387.4 Mn. Instruments still hold 44.0% of 2025 revenue but grow at 7.0%, according to Vectomat Insights.
How large is the U.S. digital PCR market?
The United States digital PCR market was worth USD 619.8 Mn in 2025, up from USD 515.0 Mn in 2023, and is forecast to grow at a 9.7% CAGR to about USD 1,564.3 Mn by 2035. It accounts for most of North America's USD 755.9 Mn, supported by CDC wastewater surveillance and clinical oncology testing, according to Vectomat Insights.
Which end user segment grows fastest in digital PCR?
Pharma and biotech companies grow fastest, at a 15.59% CAGR from USD 479.3 Mn in 2025 to USD 2,041.2 Mn in 2035, driven by vector titre and residual DNA testing for cell and gene therapies. Diagnostic laboratories remain the largest end user at 42.5% of 2025 revenue, while academic institutes grow slowest at 5.92%, according to Vectomat Insights.
How is consolidation changing the digital PCR market?
Three deals in 16 months reshaped the vendor base. Bio-Rad acquired Stilla Technologies for about USD 225 Mn in June 2025, Roche agreed to buy SAGA Diagnostics for up to USD 595 Mn in April 2026, and EQT agreed to take QIAGEN private for about EUR 10.8 Bn in October 2026. Each deal adds platforms, clinical tests or long-term investment capacity, according to Vectomat Insights.
How did VMI estimate the digital PCR market?
VMI combined a bottom-up model, built from the installed base of dPCR systems and consumable pull-through per system, with a top-down check against vendor revenue. Inputs include interviews with laboratory directors and quality-control managers, company filings, FDA and IVDR records and CDC publications. Segment, regional and country values were reconciled to the USD 1,843.6 Mn base year, according to Vectomat Insights.
Access the Complete Digital PCR Market Report
300+ pages | 98 tables & 72 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI Digital PCR Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.
About this report
Get a free sample of this report
Digital PCR Market